



Attorney Docket No.: 10004.204-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Andersen et al.

Confirmation No: 2881

Serial No.: 09/925,576

Group Art Unit: To be assigned

Filed: August 9, 2001

Examiner: To be assigned

For: Amylase Variants

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Box Sequence
Commissioner for Patents
Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:

1. Response to Notice to File Missing Parts and the Notice to Comply with Sequence Rules
2. Sequence Listing
3. Disk Containing Sequence Listing
4. Copy of Notice to Comply with Sequence Rules

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Box Sequence
Commissioner for Patents
Washington, DC 20231

on September 23, 2002.

Julie Tabarovsky
(name of person mailing paper)

Julie Tabarovsky
(signature of person mailing paper)



Attorney Docket No.: 10004.204-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Andersen et al.

Confirmation No: 2881

Serial No.: 09/925,576

Group Art Unit: To be assigned

Filed: August 9, 2001

Examiner: To be assigned

For: Amylase Variants

**RESPONSE TO NOTICE TO FILE MISSING PARTS AND TO
NOTICE TO COMPLY WITH SEQUENCE REQUIREMENTS**

Box Sequence
Commissioner for Patents
Washington, DC 20231

Sir:

In response to the Notice to File Missing Parts and the Notice to Comply with Sequence Rules dated July 23, 2002, please amend the above-identified application as follows:

IN THE SPECIFICATION:

Please delete the previously submitted Sequence Listing and insert the attached Sequence Listing (pages 1-34) at the end of the specification.

REMARKS

The Notice to Comply identified a number of alleged errors in the Sequence Listing in the computer readable form submitted. The print out of the Sequence Listing from Applicant's record of the computer readable form did not show these errors. Nevertheless, Applicants enclose a new paper copy and a new computer readable form for the Sequence Listing. The content of the paper copy and of the computer readable form is the same. This submission contains no new matter.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

Respectfully submitted,

Date: September 23, 2002



Jason I. Garbell, Reg. No. 44,116
Novozymes North America, Inc.
500 Fifth Avenue, Suite 1600
New York, NY 10110
(212) 840-0097



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/925,576	08/09/2001	Carsten Andersen	10004.204-US

CONFIRMATION NO. 2881

25908
NOVOZYMES NORTH AMERICA, INC.
500 FIFTH AVENUE
SUITE 1600
NEW YORK, NY 10110

FORMALITIES LETTER



OC000000008498735

Date Mailed: 07/23/2002

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice **MUST** be returned with the reply.

Customer Service Center
Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE